openPR Logo
Press release

European Multiple Myeloma Therapeutics Market Analysis Report by Market Data Forecast.

05-25-2017 12:05 PM CET | Health & Medicine

Press release from: Market Data Forecast

Browse And Choose From Our World Class Research Reports

Browse And Choose From Our World Class Research Reports

Market Data Forecast has published a new report “Europe Multiple Myeloma Therapeutics Market”, according to which the market is estimated at $1.8 billion in 2016 and poised to grow $2.25 billion by 2021 with a CAGR of 4.58% in the forecast period.

Multiple myeloma is a blood disorder related to leukemia and lymphoma, since it generally arises in bone marrow. In multiple myeloma, some white blood cells begin to generate abnormally within the bone marrow. Multiple myeloma majorly affects kidney, bone and blood. Patients suffering from multiple myeloma generally show several symptoms such as fatigue, loss of appetite, bone pain and increased urination.

Currently, multiple myeloma is considered incurable; however, various treatments are efficient in slowing down development of disease in the body. Initial therapy to treat the disease is known as induction therapy. Due to failed outcomes of the currently available medication, there is a high demand for effective treatment strategies to offset therapeutic dissatisfaction and increase life expectancies of patients.

The report provides a detailed analysis of drivers and constraints that controls growth of the market. Some of the drivers are:
• Increasing investment in R&D.
• Lack of availability of proper drugs.
• Increasing geriatric population and prevalence of disease.

For Full Report refer to: http://www.marketdataforecast.com/market-reports/europe-multiple-myeloma-therapeutics-market-860/

For better understanding Multiple Myeloma Therapeutics Market is segmented by treatment type, and drug type. Each sub segment is accompanied with Market Size Estimations and Y-o-Y Forecasts as well.

he Europe Multiple Myeloma Therapeutics Market is segmented on the basis of Treatment Type into Chemotherapy which is further segmented into Anthracycline Antibiotic (Melphalan (Alkeran), Liposomal doxorubicin (Doxil)) and Alkylating agent (Doxorubicin (Adriamycin), Cyclophosphamide (Neosar), Vincristine (Oncovin), Carmustine (BiCNU)) and Targeted Therapy ( Proteasome Inhibitor (Bortezomib (Velcade), Carfilzomib (Kyprolis)), by Drug Type into Corticosteroids (Dexamethasone (Decadron), Prednisone (Deltasone/Orasone)) and Immunomodulatory Agents (Thalidomide (Thalomid), Lenalidomide (Revlimid), Arsenic trioxide (Trisenox), Plerixafor (Mozobil)). With the advancement in technology targeted therapy is on a high growth due to its advantages over chemotherapy such as lesser side effects.

Free Sample for report: http://www.marketdataforecast.com/market-reports/europe-multiple-myeloma-therapeutics-market-860/request-sample

Geographically, market is analyzed under various regions namely, Germany, Italy, France, Spain and U.K. France is the largest market for multiple myeloma therapeutics in the European region

Some of the key contributors in the industry include AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC. , ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc. ,Teva Pharmaceutical Industries Ltd. ,TG Therapeutics Inc. and Johnson and Johnson. Darzalex a drug manufactured by Johnson and Johnson has got FDA approval and it can be injected to patients who have received at least three prior lines of therapy.

Customization option available at: http://www.marketdataforecast.com/market-reports/europe-multiple-myeloma-therapeutics-market-860/customize-report

The Europe Multiple Myeloma Therapeutics Market report offers wide-range of scope:

• Regional and country-level analysis that provides an individual perspective of European region and the aforementioned countries

• Know more about key areas of industry growth via detailed Segment-level analysis on basis of treatment type and drug type along with market size forecasts and y-o-y estimations

• Detailed explanation of major drivers, restraints, opportunities, and challenges (DROC) that affect the market and impact the ever-shifting market dynamics

• Strategic Analyses containing PESTLE and Porter’s Five Forces Analyses which are obtained by studying the macro & micro environmental factors that affect the market demographics

• Comprehensive listing of key market players along with Company overview, product portfolios, financials (subjected to availability), SWOT analysis and analyst overview

• Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies

• Market Outlook - Investment opportunities devised by stand in experts to provide both individuals and organizations a strong financial foothold in the market.

Enquire about the report: http://www.marketdataforecast.com/market-reports/europe-multiple-myeloma-therapeutics-market-860/inquire

Check out other related studies in the Therapeutics Segment:

Diabetic Retinopathy Market: http://www.marketdataforecast.com/market-reports/global-diabetic-retinopathy-market-936/

Hormone Replacement Therapy Market: http://www.marketdataforecast.com/market-reports/global-hormone-replacement-therapy-market-957/

Monoclonal Antibodies Market: http://www.marketdataforecast.com/market-reports/global-monoclonal-antibodies-market-1184/

Ophthalmology Therapeutics Market: http://www.marketdataforecast.com/market-reports/global-ophthalmology-therapeutics-market-1106/

Buy now at: https://www.marketdataforecast.com/cart/buy-now/europe-multiple-myeloma-therapeutics-market-860

About us
Market Data Forecast is a firm working in the areas of market research and business intelligence. We have rich experience in research across major industry segments like Healthcare, Agriculture, Food & Beverages etc. and we cater to the needs of both individual and corporate clients. Our research services contribute to key business areas like business process improvement, key decision making and developing appropriate corporate strategy. We are truly committed to our clients and other stakeholders for providing customized research services of the highest quality all the while being an organization that’s trusted for its integrity, respected for its accountability, and admired for its excellence, by both clients and competitors alike.

Contact:
Abhishek Shukla
Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: abhishek@marketdataforecast.com
Jubilee Gardens,
Hyderabad, India.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release European Multiple Myeloma Therapeutics Market Analysis Report by Market Data Forecast. here

News-ID: 551430 • Views: 470

More Releases from Market Data Forecast

Digital Therapeutics Market To Hit USD 14.4 bn by 2026
Digital Therapeutics Market Size (2021 to 2026) The worldwide digital therapeutics market size is projected to achieve USD 14.4 billion by 2026 from USD 3.26 billion in 2021, at a CAGR of 34.62% during the forecast period. DRIVING FACTORS: Growing concerns about the COVID-19 pandemic and therefore the increasing prevalence of stress and psychological state will drive the demand for digital therapies within the coming years. Since chronic diseases are often related to
Global Wearable Medical Devices Market Size To Hit USD 19538 Million by 2026
Global Wearable Medical Devices Market Size (2021 to 2026) As per our report published by Market Data Forecast, growing at a CAGR of 20.4% between 2021 to 2026, the global wearable medical devices market size is predicted to be worth USD 19538 Million by 2026. Impact of COVID-19 on the global wearable medical devices market: The outbreak of COVID-19 and widespread has a positive impact on the wearable medical devices market. The COVID-19
Veterinary Vaccines market value is estimated to grow at a CAGR of 5.5% to incre …
Overview: Veterinary Vaccines Market has seen significant growth over the past few years, due to alarm of imminent epidemics that have led to substantial losses, particularly in poultry segment. View sample and decide: https://www.marketdataforecast.com/market-reports/veterinary-vaccines-market-75/customize-report Market views: Global Veterinary Vaccines market value is estimated to grow at a CAGR of 5.5% to increase to reach a market value to USD 8.46 Billion by 2023. Drivers and restraints: Veterinary Vaccine market has displayed a noteworthy growth in recent years which
Protein Labelling Market Global Growth, Trends, And Forecast To 2024
Recent developments: Proteins are the biggest and most essential biomolecules in a living life form, as they are imperative to the working of a creature. When they are shaped inside a cell, proteins associate with different biomolecules and do jobs to keep the cell alive. Merck's FITC labeling kit gives intends to rapidly and just mark antibodies or different proteins with fluorescein. Coordinate marking of the essential immune response disposes of the

All 5 Releases


More Releases for Therapeutics

Dravet Syndrome Therapeutics- Pipeline Analysis 2018 | Zogenix, Inc., Ovid Thera …
Dravet syndrome is a form of severe myoclonic epilepsy that occurs in infants during their first year of age. If left untreated, it can be associated with other types of seizures, and status epilepticus. Children having Dravet syndrome are generally observed with poor cognitive skills and hyperactivity. Download the sample report @ https://www.pharmaproff.com/request-sample/1098 It severely affects the person’s quality of life and around 10-20% of the patient are estimated to die due
Pontine Glioma Therapeutics- Pipeline Analysis 2018 | Y-mAbs Therapeutics, Inc.
Pontine glioma is a malignant tumour which develops from the brain stem cells. Based on the grade of growth, it is categorized into anaplastic astrocytomas and glioblastoma multiforme (GBM). Download the sample report @ https://www.pharmaproff.com/request-sample/1117 Pontine glioma is more prevalent in children than adults. The common signs and symptoms of pontine glioma are squints, swallowing problems, slurred speech, facial weakness, abnormal gait, difficulty in writing and changes in personality and behaviour.
Rheumatology Therapeutics Market
Global Rheumatology Therapeutics Market: Snapshot A rising elderly population and increasing allocations for research and development of new drugs is what is serving to drive growth in the global rheumatology therapeutics market. This has led to the emergence of many new drugs. Their swift approvals by the appropriate authorities has also led to the growth in the market. A report by Transparency Market Research uncovers after in-depth study that the global rheumatology
STORM Therapeutics Joins SMi’s 9th Annual RNA Therapeutics
SMi are delighted to welcome Oliver Rausch, VP Research & Development, Storm Therapeutics, onto the speaker line-up for day 1 at RNA Therapeutics 2018! Oliver has overall responsibility for developing STORM’s target discovery platform and for the delivery of small molecule drugs from its emerging drug discovery pipeline. Oliver worked closely with scientific founders Professors Tony Kouzarides and Eric Miska to secure the initial £12m series; an investment that launched STORM
Bone Degeneration Therapeutics Market
Bone degeneration is characterized by deterioration of articular cartilage covering the joints. Cartilage aids free movement of the joint without any resistance. Reduction in flexibility of the joint due to deterioration of cartilage leads to inflammation, compressed nerves, and pain. Aging is one of the natural causes of bone degeneration, which is also fueled by several conditions such as injuries, congenital disorders, diabetes, and obesity. Symptoms of degenerative bone disorders
Global Dyslipidemia Therapeutics Market
Dyslipidemia is one of the metabolic disorder, which is described by unbalanced level and thickness of lipoproteins and triglycerides. The disorder also includes protein deficiency and over production. These disorders can be caused by increase in the serum total cholesterol, triglyceride concentrations, and low-density lipoprotein (LDL) cholesterol, and a decrease in the high-density lipoprotein (HDL) cholesterol concentration. These condition are mainly associated with cardiovascular or coronary heart disease. The other